Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Carlos Appiani
Predictors of Response to Anti-Il6 Monoclonal Antibody Therapy (Siltuximab) in Idiopathic Multicentric Castleman Disease: Secondary Analyses of Phase II Clinical Trial Data
British Journal of Haematology
Hematology
Related publications
Siltuximab: A Targeted Therapy for Idiopathic Multicentric Castleman Disease
Immunotherapy
Oncology
Allergy
Immunology
FDA Approval: Siltuximab for the Treatment of Patients With Multicentric Castleman Disease
Clinical Cancer Research
Cancer Research
Oncology
Long-Term Safety of Siltuximab in Patients With Idiopathic Multicentric Castleman Disease: A Prespecified, Open-Label, Extension Analysis of Two Trials
The Lancet Haematology
Hematology
Biologic Agents in the Treatment of Multicentric Castleman Disease
Turkish Thoracic Journal
Pulmonary
Respiratory Medicine
Multicentric Castleman Disease: An Unusual Breast Lump
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
A Phase I-Ii Clinical Trial of the Anti-Cd74 Monoclonal Antibody Milatuzumab in Frail Patients With Refractory Chronic Lymphocytic Leukaemia: A Patient Based Approach
British Journal of Haematology
Hematology
Clinicopathologic Characteristics of 342 Patients With Multicentric Castleman Disease in Japan
Modern Rheumatology
Medicine
Rheumatology
Phase I Trial of Anti-Gd2 Monoclonal Antibody Hu3F8 Plus GM-CSF: Impact of Body Weight, Immunogenicity and Anti-Gd2 Response on Pharmacokinetics and Survival
OncoImmunology
Oncology
Allergy
Immunology
Monoclonal Antibody Therapy for Non-Malignant Disease
Australian Prescriber
Pharmacology
